^
    Back
    Association details:
    Biomarker:MET exon 14 mutation
    Cancer:Gastric Cancer
    Drug:Tepmetko (tepotinib) (c-MET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non Small Cell Lung Cancer)
    Title:

    European Commission Approves TEPMETKO® (tepotinib) for Patients with Advanced NSCLC with METex14 Skipping Alterations

    Excerpt:
    Merck...today announced that the European Commission (EC) has approved once-daily oral TEPMETKO® (tepotinib) as monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma

    Excerpt:
    ......
    Trial ID:
    NCT05439993
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Tepotinib in Solid Tumors Harboring MET Alterations

    Excerpt:
    ...Patients with MET exon 14 skipping mutation detected by NGS method and c-MET copy number gain (≥6.0) in the archival or fresh tumor tissue specimen identified in K-MASTER panel....
    Trial ID:
    NCT04647838
    Less C2 evidence
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    AACR 2023
    Title:

    1082 / 26 - Effect of doublet treatment versus single-agent treatment in gastric cancers with/without MET amplification or a MET exon 14 skipping mutation

    Published date:
    03/15/2023
    Excerpt:
    Compared to ramucirumab plus paclitaxel, tepotinib plus paclitaxel inhibited the growth of GC cells with a MET exon 14 skipping mutation…
    Secondary therapy:
    paclitaxel